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Background: Emergency endovascular repair (EVAR) for ruptured abdominal aortic 
aneurysm (rAAA) may have lower operative mortality rates than open surgical repair. 
Concerns remain that the early survival benefit after  EVAR for rAAA may be offset by late 
reinterventions. The aim of this study was to compare reintervention rates and cost-
effectiveness of  EVAR and open repair for rAAA. 
Methods A retrospective analysis was undertaken of patients with rAAA undergoing EVAR 
or open repair over 6 years. A health economic model developed for the cost-effectiveness of 
elective EVAR was used in the emergency setting. 
Results: Sixty-two patients (mean age 77.9 years) underwent EVAR and 85 (mean age 75.9 
years) had open repair of rAAA. Median follow-up was 42 and 39 months respectively. There 
was no significant difference in 30-day mortality rates after EVAR and open repair (18 and 
26 per cent respectively; P = 0.243). Reintervention rates were also similar (32 and 31 per 
cent; P = 0.701). The mean cost per patient was €26 725 for  EVAR and €30 297 for open 
repair, and the cost per life-year gained was €7906 and €9933 respectively (P = 0.561). Open 
repair had greater initial costs: longer procedural times (217 versus 178.5 min; P < 0.001) and 
intensive care stay (5.0 versus 1.0 days; P = 0.015). Conversely,  EVAR had greater 
reintervention (€156 939 versus €35 335; P = 0.001) and surveillance (P < 0.001) costs.  
Conclusion: There was no significant difference in reintervention rates after EVAR or open 
repair for rAAA. EVAR was as cost-effective at mid-term follow-up. The increased 
procedural costs of open repair are not outweighed by greater surveillance and reintervention 
costs after EVAR.  
 
+A: Introduction 
Emergency endovascular aneurysm repair (EVAR) is an accepted alternative treatment to 
traditional open surgical repair for ruptured abdominal aortic aneurysm (rAAA). In the short term, 
there is evidence that it has lower morbidity and mortality rates1–3, and also shorter hospital stay, 
which may lead to lower perioperative costs. However, the recently published Amsterdam Acute 
Aneurysm (AJAX) trial4 looking at open versus endovascular repair of rAAA in a multicentre 
  
randomized clinical trial demonstrated no significant difference in combined death or severe 
complication rates between the two treatments4.  
This institution5 has previously published mid-term results following  EVAR for 
rAAA, demonstrating favourable outcomes in a cohort of 52 patients, with sustained 
perioperative survival benefit compared with open repair for at least 2 years. The durability 
and efficacy of EVAR for elective abdominal aortic aneurysm (AAA) repair has been 
established in the long term6,7; however, this is not yet well known in the setting of 
emergency repair. 
A cost-effectiveness analysis of  EVAR versus emergency open repair for rAAA, 
based on a 22-study meta-analysis8 demonstrated lower mean cumulative costs for  EVAR. 
EVAR provided a greater number of quality-adjusted life-years (QALYs) in the emergency 
setting in the short term. The Open Versus Endovascular Repair (OVER) trial9  randomized 
881 elective patients to the two techniques; EVAR had lower initial costs and improved 
survival. However, there was no demonstrable difference in survival, quality of life or cost at 
2 years following intervention. In contrast to this, a decision model using data mostly from 
the EVAR1 trial10 calculated the long-term cost-effectiveness of EVAR versus open repair, 
and found EVAR to cost £3800 (€4535; exchange rate 8 December 2013) more per patient 
with fewer lifetime QALYs11. 
EVAR is associated with lower perioperative mortality than open repair for both 
elective10 and emergency12 treatment of AAA. There remain concerns surrounding increased 
surveillance costs13 and also apparently higher reintervention rates, which may outweigh the 
early cost benefit14. There is currently little evidence in the emergency setting regarding the 
cost-effectiveness of either type of AAA repair at mid-term follow-up. This study used 
reporting standards15 , defining short term as 30 days and 1 year following intervention, mid-
term as greater than 2 years and long term beyond 5 years.  
The aim of this study was to compare reintervention rates, mid-term outcome and 
cost-effectiveness in cohorts undergoing  EVAR and open repair for rAAA. 
+A: Methods 
A retrospective analysis of a prospectively collated database was carried out on patients with 
rAAA presenting to Cambridge University Hospitals, a tertiary referral vascular unit in the 
  
UK, between February 2006 when the database began and January 2012. Patients randomized 
to treatment as part of the Immediate Management of Patients with Ruptured Aneurysm: 
Open Versus Endovascular Repair (IMPROVE) trial16,17 were included. The database was 
verified against electronic hospital records, including operative records, discharge and 
outpatient letters, imaging and blood transfusion records to ensure data were as complete and 
accurate as possible. This database included all patients with rAAA, defined as radiographic 
or intraoperative evidence of retroperitoneal or free intraperitoneal rupture.  Site-specific 
ethical approval was granted for patients randomized within the IMPROVE trial. The study 
was registered with the Audit Department of Addenbrooke’s Hospital. 
Patients presenting with rAAA were managed using the principle of ‘permissive 
hypotension’, with transfusion of packed red blood cells and other transfusion products as 
necessary. The hospital has previously reported low palliation rates for patients presenting 
with rAAA18. The comparative costs of palliation for rAAA are not included in this analysis.  
The choice of treatment for rAAA was based on surgeon’s preference and aneurysm 
anatomy during the interval from commencement of the study until October 2009, beyond 
which the unit began randomization as part of the IMPROVE trial11. IMPROVE randomized 
patients with a clinical diagnosis of rAAA to either immediate transfer to theatre for open 
repair or computed tomography (CT) followed by EVAR if anatomically appropriate. All 
patients had rAAA confirmed by either CT or intraoperative evidence of rupture. EVAR was 
the treatment of choice in those deemed anatomically suitable both before the start of 
IMPROVE, or during this study for patients who were excluded from randomization. Usually 
this occurred because anatomical suitability had been established before recruitment. Five 
consultant vascular surgeons managed all patients, with roughly even proportions of each of 
the surgeons performing the two techniques. Those undergoing EVAR had insertion of either 
an aortouni-iliac device with a femorofemoral crossover, or a bifurcated graft, performed 
according to aneurysm anatomy, patient haemodynamic stability and surgeon preference.  
During the whole study patients who had undergone EVAR returned to outpatients 6 
weeks after discharge. They were then seen in a dedicated EVAR surveillance clinic at 6 and 
  
12 months, and annually thereafter.  Aortic CT was done after 3 and 12 months, followed by 
annual duplex imaging, plain abdominal X-ray and clinical review thereafter. Surveillance 
imaging recorded aneurysm size, the presence of endoleak, stent-graft migration and limb 
kinking or stenosis. CT beyond 12 months was used only for aneurysm enlargement or 
endoleak detected on duplex surveillance. Patients who had open repair were seen in 
outpatients  at 6 weeks then 6 months, with no routine imaging, and then discharged unless 
further review was indicated clinically. Additional selective imaging was requested at the 
discretion of the operating surgeon.  
+B: Cost-effectiveness analysis 
The cost-effectiveness analysis was performed by summation of all costs for each group at 
two different time intervals – perioperative costs associated with the index admission, and 
those incurred as part of follow-up, including surveillance imaging and outpatient clinical 
review, as well as all reinterventions. Table 1 details the cost assumptions used for this 
calculation, taken from the financial records of the institution. There were three levels of 
care: intensive care unit (ICU; level 2 and 3 beds), high-dependency unit (level 1 beds) and 
ward-based. There were different theatre costs for EVAR and open repair owing to the 
different staffing requirements for the two procedures, and these included heating, lighting, 
clean air, Private Finance Initiative repayments and theatre share of managerial costs. The 
cost of a stent-graft for  EVAR was fixed at €5955 per case, irrespective of the number of 
stents or graft limbs used; this relatively low stent-graft cost reflects the high EVAR unit 
volume. In addition to this, a fee of €596 for needles, wires, sheaths, balloons and catheters 
required for EVAR was included in the analysis (ESSK-3 package; Cook Medical Europe, 
Limerick, Ireland). An overall cumulative cost for each group was calculated for both time 
intervals. The total number of days of follow-up, calculated as the number of days from 
hospital discharge following the index admission to either date of death or last note review, 
was then summated. A cost per day and year per patient following successful treatment was 
then calculated. All costs in this analysis were calculated in euros based on the exchange rate 
on 1 November 2013, which was €1.19099 per £1 GBP and quoted to the nearest euro.  
Finally, incremental cost-effectiveness ratios (ICERs) were calculated, adopting a 
similar approach to that described previously8.  As quality of life was not measured during 
follow-up, it was assumed to be similar to that following elective repair19. Quality-of-life data 
collected after the EVAR1 trial20 were used to estimate the effect of treatment in QALYs.  To 
  
account for reductions in quality of life in the immediate postintervention phase, it was 
assumed that reintervention caused similar short-term changes in quality of life. 
+B: Statistical analysis 
The data were analysed on an as-treated basis. This was an observational study, so crossover 
rates among those treated in IMPROVE were not assessed.  Continuous variables are 
presented as mean(s.d.) or median (range). Unpaired t test was used for analysis of normally 
distributed continuous variables and Mann–Whitney U test for variables with a non-normal 
distribution. Pearson’s 2 analysis and Fisher’s exact test were used for binomial data. 
Overall survival and freedom from reintervention were analysed using Kaplan-Meier–plots, 
with significance of differences between the groups calculated by Mantel–Cox log rank test. 
All statistical analyses were two-sided and a significance level of P < 0.050 was set. 
Statistical analysis was undertaken using GraphPad Prism® version 5 (GraphPad Software, 
La Jolla, California, USA). 
+A: Results 
There were 147 patients included in the study. Sixty-two patients (mean 77.9 (56–97) years) 
underwent  EVAR and 85 (75.9 (range 58–92) years) had open surgical repair for RAAA. 
The median  follow-up was 42 (4–76) and 39 (2–75) months for EVAR and open repair 
respectively. Patient demographics were similar between the two treatment groups (Table 2). 
Overall there were 125 men (85.0 per cent) with a mean age of 77.2 (56–97) years.   
 Before the start of IMPROVE, 87 patients were included in the rAAA database (41 
EVAR, 46 open repair) and 60 patients were added (21 EVAR, 39 open repair) following 
recruitment to IMPROVE. There was a bias towards open repair that explains the discrepancy 
in numbers between treatment methods, which had previously been roughly 50 per cent for 
each procedure4. Ten patients were not offered intervention for rAAA during the study 
interval. This low turn-down rate may not reflect that of the entire catchment population, as it 
may not include all patients with rAAA not referred from receiving hospitals. 
+B: Outcomes  
Some 33 (22.4 per cent) of 147 patients died within 30 days . There was no difference 
between EVAR and open repair (18 and 26 per cent respectively; P = 0.243). Similarly, 
  
mortality rates during follow-up were not significantly different (44 and 50 per cent 
respectively; P = 0.697).  
Early reinterventions, required during the index admission, were significantly more 
common in the open repair group (P = 0.002), whereas the EVAR group had significantly 
more late interventions (P = 0.008)  after discharge from the index admission (Fig. 1). There 
were 22 early reinterventions after open repair; these included six procedures for mesenteric 
ischaemia, two for perforated peptic ulcer and 14 revascularizations for ischaemic legs. There 
were four late reinterventions after open repair: two for adhesions, one aortocaval fistula 
repair and one aortoduodenal fistula repair. After EVAR there were only four early 
reinterventions, all  related to femorofemoral bypass graft infection or leg ischaemia, There 
were 16 late reinterventions after EVAR, for aortic endoleak (7), stent-graft kinking (2), 
femorofemoral graft sepsis (2) and graft thrombosis (1).  Overall rates of reintervention were 
similar in the two groups (P = 0.701).  
Although there appeared to be an initial survival benefit in patients with rAAA  
treated by EVAR, there was no significant difference in overall survival rates for the two 
procedures (P = 0.203) and, in addition, no significant benefit  at any time point following 
the intervention (P = 0.357) (Fig. 2). 
+B: Cost-effectiveness analysis 
The overall perioperative cumulative costs for the two procedures are detailed in Table 3. 
Costs were higher for open repair: €29 881 per patient compared with €24 194 for EVAR. 
The cost per patient treated successfully and discharged from hospital was also less in the 
EVAR group: €30 613 versus €42 332, a difference of €11 719 per patient.  
Major factors influencing the perioperative cost included a significantly lower median 
ICU stay after EVAR (1.0 versus 5.0 days; P = 0.015) with a trend towards a shorter overall 
hospital  stay (9.5 versus 15.0 days; P = 0.268). The median procedural duration was 
significantly lower for  EVAR (178.5 versus 217 min; P < 0.001) as was the median amount 
of packed red cells transfused (3.5 versus 7 units;  P < 0.001). Conversely the cost of stent-
grafts, including femorofemoral crossover grafts, was significantly higher in the EVAR 
group.  
Patients who had EVAR required significantly more follow-up appointments (median   
2 (1–7) versus 1 (1–3); P < 0.001) and follow-up imaging (CT and ultrasound imaging: 
  
median 2 versus 0 scans; P < 0.001). EVAR surveillance and reintervention costs were 
significantly higher, equating to an overall difference of €121 604 between the two 
procedures.  
Overall costs for open repair and EVAR were similar (P = 0.433) (Table 5); EVAR 
was €3572 cheaper overall per patient and €2027 per year survived.  
The mean QALY per patient during follow-up was 1.790 in the EVAR group 
compared with 1.355 in the open repair group.  Duration of follow-up was similar in the two 
groups,  so EVAR resulted in a gain of QALYs, with an ICER of approximately €–
4933/QALY for EVAR compared with open repair, in favour of EVAR. 
+A: Discussion 
This study suggests that EVAR was as cost-effective as open surgical repair for rAAA for up 
to 3 years after intervention.  Open repair was costly in the perioperative phase, whereas 
EVAR had increased follow-up and reintervention costs.  EVAR was associated with lower 
mortality rates at both 30 days and at mid-term, but this survival advantage did not reach 
statistical significance. In the long term EVAR may become more expensive with increasing  
follow-up costs, as well as an increasing proportion of patients requiring reintervention.  In 
addition, with the adoption of enhanced recovery programmes21, it may be possible to reduce 
the perioperative costs of open repair. 
Compared with the meta-analysis8 of cost-effectiveness of open repair versus EVAR 
for rAAA, this study demonstrated higher overall costs per patient in both groups when 
converted to GBP (EVAR: £22 439 versus £17 422 in the meta-analysis; open repair £25 439 
versus £18 930). These increases may reflect both a degree of inflation, but also the fact that 
the present study detailed actual costs, rather than the assumptions used in the meta-analysis. 
The costs incurred are specific to both the UK healthcare system and the Cambridge Vascular 
Unit, and so may not reflect costs elsewhere. In particular, the relatively low stent-graft costs 
reflect local negotiations in a high-volume elective EVAR unit.  
The OVER trial9 compared the cost-effectiveness of elective EVAR and open repair 
There was  a significant difference in cost during the initial perioperative stay (US $37 068 
versus $42 970; P = 0.04) (€27 069 versus €31 376; exchange rate 8 December 2013); 
however, at 2-year follow-up this difference was no longer significant ($5019 (€3665) 
  
difference; P = 0.35). Overall, the costs were higher for both techniques, reflecting  higher 
healthcare costs in North America. 
Clearly, an early death after intervention for rAAA conveys a cost reduction to the 
technique. The higher 30-day mortality rate after open repair should have reduced overall 
early costs of this procedure. Despite this, the perioperative costs were significantly higher 
after open repair, so the cost–benefit analysis may underestimate the early benefit of EVAR. 
Some increased costs of follow-up in the  EVAR group may be acceptable given the 
reduction in 30-day mortality rates. 
There are a number of limitations to this study. Before involvement in the IMPROVE 
study, patients with rAAA were offered  EVAR if anatomically suitable.  EVAR was still 
offered to some patients outside IMPROVE if they did not meet the inclusion criteria for the 
study (mainly patients in whom anatomical suitability for EVAR had been established by 
imaging at other hospitals before transfer). There may, therefore, have been selection bias 
before IMPROVE. This may be most relevant in patients deemed to have aneurysm anatomy 
unsuitable for EVAR. These patients have rAAAs that may be technically more challenging, 
requiring a suprarenal clamp during open repair, and potentially resulting in increased 
morbidity and mortality. Undertaking straightforward procedures with EVAR may create a 
selection bias, with more difficult cases undergoing open repair resulting in increased costs 
and reintervention rates in this group.  Before IMPROVE, the majority of patients treated 
with open repair were anatomically unsuitable for EVAR.  As a result, it was not possible to 
perform case matching in the present study. Dick and colleagues22  have recently 
demonstrated, in the setting of open repair for rAAA, that anatomical suitability for EVAR is 
an independent predictor of survival22.  Some also believe that EVAR is more likely to be 
offered to more stable patients, introducing further bias; this was not case in Cambridge5. In 
addition, there was no attempt to measure quality of life as part of the present study; the 
QALY calculations were based on results from other studies.  
Follow-up after open repair is less rigorous than that following EVAR. Many 
potential reinterventions after open repair may not directly involve a vascular specialist, for 
example incisional hernia or adhesion-related bowel obstruction. This increases the 
possibility that reinterventions after open repair are under-reported, so follow-up and 
reintervention costs may be underestimated.  
  
The accumulating number of reinterventions after EVAR with increasing follow-up 
raises concerns about the long-term durability of this technique for rAAA, and also longer-
term cost-effectiveness. The excess rate of early reinterventions after open repair was 
overtaken by EVAR by 5 years of follow-up. Improving endograft systems to prevent late 
intervention would significantly change the cost balance between the techniques.  
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Fig. 1 Freedom from reintervention after endovascular aneurysm repair (EVAR) versus open 
surgical repair of ruptured aortic aneurysm.  Dotted lines represent 95 per cent confidence 
intervals. P = 0.148 (Mantel–Cox log rank test)  
Fig. 2 Survival after endovascular aneurysm repair (EVAR) versus open surgical repair of 
ruptured aortic aneurysm. Dotted lines represent 95 per cent confidence intervals. There was 
no overall difference in survival between the two interventions (P = 0.206) nor benefit at any 





Table 1 Unit cost assumptions for this hospital used to perform the cost-effectiveness analysis 
 Cost (€) 
Intensive care unit bed  (1 day) 1429 
High-dependency unit bed (1 day) 501 
Ward bed (1 day) 395 






EVAR graft 5955 
EVAR disposables  596 
Aortic tube graft 411 
Femerofemoral crossover graft 250 
Emergency department costs (0.5 h ) 79 
Packed red blood cells (1 unit) 146 
Platelets (1 unit) 249 
Outpatient appointment 170 
Computed tomography of aorta 120 
Duplex imaging of aorta 58 
EVAR, endovascular aneurysm repair.  
 
 
Table 2  Characteristics of 147 patients presenting with ruptured abdominal aortic aneurysm 
 Whole cohort 
(n = 147) 
EVAR 
(n = 62) 
Open repair 
(n = 85) P* 
Mean(s.d.) age 
(years) 
76.8(7.5) 77.9(7.0) 75.9(7.7)  0.104† 
Sex ratio (M : F) 125 : 22 51 : 11 74 : 11  0.420 
Ischaemic heart 
disease  
65 27 38  0.889 
Diabetes mellitus 8 5 3  0.282‡ 
Chronic kidney 
disease 





29 11 18  0.605 
EVAR, endovascular aneurysm repair. *2 test, except †t test and ‡Fisher’s exact test.  
  
 
Table 3  Resource use and costs for perioperative care after endovascular or open repair for ruptured 
abdominal aortic aneurysm 
 EVAR (n = 62) Open repair (n = 85) 
P* Resource use Total cost (€) Resource use Total cost (€) 
ICU stay (days) 319.5  456 566 897  1 281 813 0.015 
HDU stay (days) 64  32 064 160  80 160 0.064 
Ward stay (days) 1005  396 975 1840  726 800 0.268 
Theatre time (h) 197  152 281 347  273 436 < 0.001 
Packed red blood 
cells (units) 
261  38 106 758  110 668 < 0.001 
Platelets (units) 13  3237 100  24 900 < 0.001 
Grafts 62 369 210 85 34 935 < 0.001 
EVAR 
disposables 
62 36 952 0 0 < 0.001 
Femorofemoral 
crossover graft 
39 9750 2 500 < 0.001 
Emergency 
department (h) 
31  4898 42.5  6715  1.000 
      
Total cost   1 500 039  2 539 927 0.206 
Cost of perioperative care included all costs associated with the index admission. EVAR, 
endovascular aneurysm repair; ICU, intensive care unit; HDU, high-dependency unit. *Comparison of 
costs (t test). 
  
  
Table 4  Resource use and costs for follow-up and reintervention after endovascular or open repair for 
ruptured abdominal aortic aneurysm 
 
 EVAR (n = 51) Open repair (n = 63) 
P* 
Resource 
use Total cost (€) 
Resource 
use Total cost (€) 
Outpatient 
appointments 
151  25 670 53 9010 < 0.001 
Computed 
tomography  
110 13 200 15 1800 < 0.001 




12 17 148 5 7145 0.173 
Ward stay – 
reintervention 
(days) 
253 99 935 44 17 380 0.010 
      
Total cost  156 939  35 335 0.001 




Table 5 Overall costs  
 EVAR (n = 62) Open repair (n = 85) P* 
Overall cost (€) 1 656 978 2 575 262  0.433 
Mean cost per patient 
(€) 
26 725 30 297  
No. of days of follow-up 76 495 94 635  
Cost per day of survival 
(€) 
21.66 27.21 0.561 
Cost per year of survival 
(€) 
7906 9933 




Figure 1 –  
                     
Freedom from reintervention























 Months 0 10 20 30 40 50 60 
Number 
at risk 
EVAR 62 40 34 23 18 11 4 
OSR 85 42 36 22 15 11 9 
 
Figure 2  
                   
Survival Following rAAA























 Months 0 10 20 30 40 50 60 
Number 
at risk 
EVAR 62 43 35 30 24 16 6 
OSR 85 44 39 24 17 14 10 
 
